Global Spinal Fusion Device Market Forecast Report 2024-2030, Featuring Medtronic, Stryker, Zimmer Biomet, Orthofix Medical, NuVasive, Globus Medical, Xtant Medical & Alphatec

Global Spinal Fusion Device Market Forecast

The “Global Spinal Fusion Device Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis” report has been added to ResearchAndMarkets.com’s offering.

On Track

The global spinal fusion devices market is on track to achieve significant growth, with projections suggesting an increase in market size to US$ 9.99 Billion by 2030. This growth trajectory reflects a noteworthy compound annual growth rate (CAGR) of 3.98% between 2024 and 2030. A new comprehensive analysis highlights crucial insights and industry trends driving this expansion.

With an ever-increasing elderly population and rising incidences of spine-related disorders, the spinal fusion devices market is witnessing a consistent rise in demand. Advancements in medical technology have gradually extended the scope of spinal fusion surgery to treat a variety of conditions, leading to an upsurge in surgical procedures globally.

Industry Trends and Growth Drivers

  • Rising Geriatric Population: The aging demographic poses a high risk for spinal disorders, necessitating increased reliance on spinal fusion devices.
  • Technological Advancements: Continuous innovation including minimally invasive surgery techniques enhances the market demand for spinal fusion devices.
  • Prevalence of Spinal Conditions: With a high incidence of spinal cord injuries and related ailments, the need for efficient treatments is on the rise, propelling the market forward.

The market analysis delves into the different segments within the spinal fusion devices industry, including product types such as cervical devices, thoracolumbar devices, interbody devices, and biologics. The cervical segment is anticipated to witness substantial growth, propelled by technological advancements and increasing patient awareness.

Category Insights and Market Dynamics

  • Minimally Invasive Surgery: Dominating the market in revenue share, minimally invasive surgeries offer numerous benefits over traditional open spine surgery, thereby gaining preference among healthcare providers and patients.
  • Hospitals as Prime End-Users: Hospitals maintain the largest market share, accredited to their full range of services for spinal care and capacity for complex procedures.

Geographically, the Asia Pacific region is poised for a significant leap in the spinal fusion device market, with factors like an aging population, growing occurrences of road accidents, and advancements in healthcare infrastructure contributing to this growth.

Market Leaders and Innovators

  • Medtronic Plc
  • Stryker Corporation
  • Zimmer Biomet Holdings
  • Orthofix Medical Inc.
  • NuVasive Inc.
  • Globus Medical Inc.
  • Xtant Medical Holdings
  • Alphatec Holdings Inc.

The report offers an in-depth look at the present market scenario, encompassing a detailed company analysis that sheds light on the recent developments and revenue metrics of the industry’s leading players. These insights serve as crucial tools for stakeholders and market participants seeking to understand and navigate the evolving landscape of the spinal fusion device sector.

The comprehensive market analysis is a vital resource for those looking to grasp the full scope of the spinal fusion device industry, illustrating the dynamic interplay between technological innovations, market forces, and the growing demand due to demographic shifts. Such data underscores the potential of the spinal fusion device market to transform spine health treatment and improve patient outcomes significantly.

Report Segmentation

Product Type 

  • Cervical Devices
  • Thoracolumbar Devices
  • Interbody Devices
  • Biologics

Surgery Type

  • Open Surgery
  • Minimally Invasive

End Users

  • Hospitals
  • Specialty Clinics
  • Others

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version